Clostridium praeparatum microbial anti-inflammatory molecule as well as screening method and application thereof

By screening and applying Clostridium prazilian microbial anti-inflammatory molecules, especially the MAM protein of CNCM I 4644 strain, the existing side effects of drugs for treating inflammatory bowel disease and uncertainty in fecal bacteria transplantation are solved, and at low doses It significantly inhibits the expression of NF-κB signaling pathway and TNFα, and significantly improves the therapeutic effect of inflammatory bowel disease.

CN118955659AActive Publication Date: 2024-11-15GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

Patent Information

Application Number
CN202410699193.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-31
Publication Date
2024-11-15
Estimated Expiration
2044-05-31

AI Technical Summary

Technical Problem

The existing drugs for the treatment of inflammatory bowel disease have side effects, are not lasting for efficacy and have high recurrence rates, and there is uncertainty in the screening and preparation of fecal bacteria transplantation, resulting in large differences in the treatment effect and lack of effective inhibition of NF-κB signaling pathway and TNFα. substance.

Method used

Screening and providing a Clostridium prazilian microbial anti-inflammatory molecule, protein encoded by amino acid sequence or nucleotide sequence, has a powerful anti-inflammatory effect and can inhibit the expression of NF-κB signaling pathway and TNFα at low doses, using Luciferase reporter vector method The MAM protein of CNCM I 4644 strain with more than 90% anti-inflammatory effect was screened in intestinal epithelial cell lines.

Benefits of technology

It has achieved a significant inhibition of the expression of NF-κB signaling pathway and TNFα at low doses, with stronger anti-inflammatory effects, and has a more significant inhibitory effect than the representative strain A2-165, and is more obvious in the mouse enteritis model. therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955659A_ABST
    Figure CN118955659A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to a clostridium praeparatum microbial anti-inflammatory molecule as well as a screening method and application of the clostridium praeparatum microbial anti-inflammatory molecule. The amino acid sequence of the clostridium praeparatum microbial anti-inflammatory molecule is shown as (a) or (b); (a) the amino acid sequence is as shown in SEQ ID NO.1; and (b) a protein which is derived from (a), has anti-inflammatory activity and is obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence in (a). Compared with a microbial anti-inflammatory molecular protein of a representative strain A2-165 of a Faecalibacterium genus, the inhibition effects of the microbial anti-inflammatory molecular protein on an NF-kB signal channel and an inflammatory factor TNF alpha are 50% and 56% respectively, while the anti-inflammatory effect (inhibiting the NF-kB signal channel) of the clostridium praeparatum microbial anti-inflammatory molecule screened by the application can reach 90% or above, and the clostridium praeparatum microbial anti-inflammatory molecule has the advantages of small dosage and strong anti-inflammatory effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biotechnology, and in particular to an anti-inflammatory molecule of Faecalibacterium prausnitzii microorganism and a screening method and application thereof. Background Art

[0002] Inflammatory bowel disease (IBD) is one of the intractable diseases of the digestive tract, mainly including Crohn's disease (CD) and ulcerative colitis (UC). Compared with other digestive tract diseases, IBD has the characteristics of high cost of treatment, difficult to cure and high recurrence rate, which seriously affects the quality of life of patients.

[0003] In the immune response, NF-κB, as the most critical transcription factor in the inflammatory response, participates in the innate and adaptive immune responses. In the intestinal tissues of patients with IBD or other acute and chronic enteritis, the NF-κB signaling pathway is activated, inducing the production of a large number of proinflammatory cytokines and inducing inflammation. These cytokines are divided into two categories: one is cytokines that promote innate immunity, such as type I interferon (IFNβ), IL-12 and macrophage chemokines; the other is cytokines that promote acquired immunity, such as IL-1, IL-2, IL-6, IL-8, IL-12, IL-18 and type II interferon (IFNγ). Tumor necrosis factor TNFα is one of the most important proinflammatory factors, which can be expressed in intestinal epithelial cells, endothelial cells and immune cells in the propria. TNFα is an important regulatory factor in the pathogenesis of IBD. First, TNFα can induce the destruction of epithelial cell tight junctions, change the intestinal epithelial barrier function, and affect intestinal permeability; second, TNFα can promote the expression of CEACAM6, mediate immune tissue damage, and increase intestinal bacterial invasion and infection.

[0004] At present, the commonly used drugs for the treatment of IBD in clinical practice include aminosalicylic acids, glucocorticoids, antibiotics, and immunosuppressants, which can all play a role by inhibiting the NF-κB signaling pathway and inflammatory response. Infliximab, adalimuma, and certolizumab are also therapeutic drugs targeting TNFα. However, these drugs all have obvious side effects, the efficacy is not lasting and is prone to relapse, and the treatment effects on different patients vary greatly. Therefore, there is an urgent need to find safer and more effective substances that inhibit the NF-κB signaling pathway and TNFα.

[0005] Studies have shown that the intestinal microbiome is essential for maintaining intestinal homeostasis and human health, and changes in the intestinal microbiome are closely related to chronic inflammation-related diseases in the intestine. Fecal microbiota therapy, also known as fecal microbiota transplantation (FMT) or intestinal microbiota transplantation, is to transplant the functional flora in the feces of healthy people into the intestines of patients in a certain way to restore the diversity of healthy intestinal flora and achieve the treatment of intestinal and extraintestinal diseases. At present, fecal microbiota transplantation has been regarded as a special organ transplantation for inflammatory bowel disease, irritable bowel syndrome, metabolic syndrome, neuroplastic and neurodegenerative diseases, autoimmune bowel disease, etc. However, fecal microbiota transplantation is limited by the screening of healthy donors, the preparation of fecal microbiota, the acceptance of patients, the treatment effect, etc. The screening of healthy donors for fecal microbiota transplantation is extremely strict. The diet, sleep quality, and drug use of healthy donors will affect the composition and abundance of their flora, and ultimately affect the treatment effect. Therefore, it is very important to screen effective strains and their components for the treatment of inflammatory responses in the digestive system.

[0006] Faecalibacterium prausnitzii (F.prausnitzii) is an anaerobic bacterium that mainly exists in the terminal ileum and ileocecal region. It accounts for about 5-15% of the total fecal flora of healthy adults and is one of the most abundant commensal bacteria in the intestinal flora of healthy adults. In previous studies, it was found that intestinal flora, especially F.prausnitzii, plays a very important role in the occurrence, development and prognosis of UC. The degree of reduction of F.prausnitzii is closely related to the severity and prognosis of IBD. In addition, the abundance of F.prausnitzii is also significantly reduced in the feces of NAFLD patients, and supplementation of F.prausnitzii can improve lipid deposition in NAFLD mice. In recent years, scientists have discovered a 15kDa protein in the culture supernatant of F.prausnitzii, which can not only inhibit the NF-κB signaling pathway of intestinal epithelial cells, but also significantly reduce DNBS or DSS-induced intestinal inflammation in mice. It is called Microbial Anti-inflammatory Molecule (MAM). According to literature reports and the strain classification database LPSN, the genus Faecalibacterium prausnitzii is divided into 7 species. Exploring the anti-inflammatory effect of each strain is very important for screening probiotic strains. MAM is the most important anti-inflammatory protein of F.prausnitzii, and the role of the strain can be determined by screening the anti-inflammatory effect of MAM.

[0007] Currently, there is a lack of effective treatments for inflammatory bowel disease, irritable bowel syndrome, metabolic syndrome, and autoimmune bowel disease. Fecal microbiota transplantation, as a treatment method, is limited by the selection of healthy donors, the preparation of fecal microbiota, the diversity and uncertainty of components, and its therapeutic effect varies greatly. As one of the most abundant commensal bacteria in the intestinal flora of healthy adults, studies have reported that Faecalibacterium prausnitzii can improve the progression of inflammatory bowel disease and non-alcoholic fatty liver disease. However, the effects of different Faecalibacterium prausnitzii strains are not consistent. Summary of the invention

[0008] The purpose of this application is to overcome the shortcomings of the above-mentioned prior art and provide a microbial anti-inflammatory molecule of Faecalibacterium prausnitzii and its screening method and application. The anti-inflammatory effect of the microbial anti-inflammatory molecule of Faecalibacterium prausnitzii screened in this application can reach more than 90%. It has the advantages of small dosage and strong anti-inflammatory effect.

[0009] To achieve the above purpose, the technical solution adopted by this application is:

[0010] In a first aspect, the present application provides a Faecalibacterium prausnitzii microbial anti-inflammatory molecule, the amino acid sequence of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule is as shown in (a) or (b);

[0011] (a) the amino acid sequence is shown in SEQ ID NO.1;

[0012] (b) A protein derived from (a) having anti-inflammatory activity, wherein the amino acid sequence in (a) is substituted, deleted or added with one or more amino acids.

[0013] As a preferred embodiment of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule described in the present application, the nucleotide sequence of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule is shown in SEQ ID NO.2.

[0014] The microbial anti-inflammatory molecules of Faecalibacterium prausnitzii screened in this application can have a strong anti-inflammatory effect under the premise of low-dose use. Compared with the representative strain A2-165 of the Faecalibacterium genus, the microbial anti-inflammatory molecule protein has an inhibitory effect on the NF-κB signaling pathway and the inflammatory factor TNFα of 50% and 56% respectively, while the anti-inflammatory effect (inhibition of the NF-κB signaling pathway) of the microbial anti-inflammatory molecules of Faecalibacterium prausnitzii screened in this application can reach more than 90%.

[0015] Preferably, the Faecalibacterium prausnitzii microbial anti-inflammatory molecule is derived from the CNCM I 4644 strain (the nucleotide sequence can be obtained from the NCBI database).

[0016] In a second aspect, the present application provides a nucleic acid molecule encoding the above-mentioned Faecalibacterium prausnitzii microbial anti-inflammatory molecule.

[0017] In a third aspect, the present application provides an expression vector carrying the above-mentioned nucleic acid molecule.

[0018] As a preferred embodiment of the expression vector described in the present application, the expression vector includes the eukaryotic expression vector pcDNA3.1.

[0019] In a fourth aspect, the present application provides a host cell, wherein the host cell comprises the above-mentioned Faecalibacterium prausnitzii microbial anti-inflammatory molecule or nucleic acid molecule or expression vector.

[0020] As a preferred embodiment of the host cell described in the present application, a luciferase reporter gene vector of NF-κB or a luciferase reporter gene vector of the inflammatory cytokine TNFα promoter is introduced into the host cell.

[0021] In a fifth aspect, the present application provides a method for screening the above-mentioned Faecalibacterium prausnitzii microbial anti-inflammatory molecules, comprising the following steps:

[0022] S1. Obtain the genome sequences of different strains of Faecalibacterium from the NCBI database;

[0023] S2. The microbial anti-inflammatory molecules of different strains of Faecalibacterium are cloned into eukaryotic expression vectors, and co-transfected into host cells with NF-κB luciferase reporter gene vector or luciferase reporter gene vector of inflammatory cytokine TNFα promoter, to screen Faecalibacterium prausnitzii microbial anti-inflammatory molecules that have inhibitory effects on the expression of NF-κB and TNFα.

[0024] This application is designed for the common targets for the treatment of clinical intestinal inflammation, namely the NF-kB signaling pathway and the expression of the pro-inflammatory factor TNFα, and introduces a luciferase reporter gene vector, a method with high sensitivity and accurate quantification, to screen the microbial anti-inflammatory molecules of the genus Faecalibacterium in an intestinal epithelial cell line.

[0025] Preferably, the method for screening the anti-inflammatory molecules of Faecalibacterium prausnitzii microorganisms comprises the following steps:

[0026] 1. Download the genome sequences of 71 strains of the genus Faecalibacterium from the NCBI database, find out the gene sequences encoding microbial anti-inflammatory molecules through sequence comparison and translate them into amino acid sequences, and perform evolutionary analysis on the amino acid sequences of the above microbial anti-inflammatory molecules using MEGA-X software, and find that they can be divided into at least 7 lineages.

[0027] 2. Representative strains were selected from the seven lineages of the genus Faecalibacterium, and their microbial anti-inflammatory molecule sequences were cloned into eukaryotic expression vectors. They were co-transfected into the intestinal epithelial cell line HCT116 with the luciferase reporter gene vector of NF-κB or the luciferase reporter gene vector of the inflammatory cytokine TNFα promoter, and MAM proteins that inhibited the expression of NF-κB and TNFα were screened. It was found that strains of lineage A had a stronger inhibitory effect on NF-κB and TNFα.

[0028] 3. Five strains of lineage A were further screened, and their microbial anti-inflammatory molecule sequences were cloned into eukaryotic expression vectors, and co-transfected with NF-κB luciferase reporter gene vector or luciferase reporter gene vector of inflammatory cytokine TNFα promoter into the intestinal epithelial cell line HCT116, thereby screening out the MAM protein with the strongest inhibitory effect on the expression of NF-κB and TNFα, namely, the Clostridium prausnitzii microbial anti-inflammatory molecule of CNCM I 4644 strain.

[0029] 4. Different doses of CNCM I 4644-MAM ​​eukaryotic expression vectors were co-transfected with NF-κB luciferase reporter gene vectors or inflammatory cytokine TNFα promoter luciferase reporter gene vectors into the intestinal epithelial cell line HCT116. It was found that the anti-inflammatory molecule of Faecalibacterium prausnitzii microorganism still had a strong anti-inflammatory effect even when the expression level was very low.

[0030] In a sixth aspect, the present application provides a method for clustering Faecalibacterium prausnitzii, and performs phylogenetic tree analysis on the amino acid sequence of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule.

[0031] The above-mentioned clustering method performs evolutionary tree analysis through the amino acid sequence of the anti-inflammatory molecule MAM of the Faecalibacterium prausnitzii microorganism, rather than the traditional 16sRNA sequence. The method is more conducive to screening the anti-inflammatory function of MAM protein.

[0032] In a seventh aspect, the present application provides an anti-inflammatory drug, which includes the above-mentioned Faecalibacterium prausnitzii microbial anti-inflammatory molecule.

[0033] In some specific embodiments, the mass concentration of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule is 0.1-0.8 μg / well. Preferably, the mass concentration of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule is 0.1 μg / well.

[0034] In an eighth aspect, the present application provides the use of Faecalibacterium prausnitzii microbial anti-inflammatory molecules in the preparation of anti-inflammatory drugs.

[0035] The Faecalibacterium prausnitzii microbial anti-inflammatory molecules of the present application can treat intestinal inflammations such as inflammatory bowel disease, irritable bowel syndrome, metabolic syndrome and autoimmune bowel disease.

[0036] Compared with the prior art, this application has the following beneficial effects:

[0037] The present application provides a microbial anti-inflammatory molecule of Faecalibacterium prausnitzii and its screening method and application. Compared with the representative strain A2-165 of the genus Faecalibacterium, the microbial anti-inflammatory molecule protein has an inhibitory effect of 50% and 56% on the NF-κB signaling pathway and the inflammatory factor TNFα, respectively, while the anti-inflammatory effect (inhibition of the NF-κB signaling pathway) of the microbial anti-inflammatory molecule of Faecalibacterium prausnitzii screened out in the present application can reach more than 90%, with the advantages of small dosage and strong anti-inflammatory effect. In addition, the present application is designed for the common targets of clinical intestinal inflammation treatment, namely the expression of the NF-κB signaling pathway and the pro-inflammatory factor TNFα, and introduces a luciferase reporter gene vector, a method with good sensitivity and accurate quantification, to screen the microbial anti-inflammatory molecules of the genus Faecalibacterium on the intestinal epithelial cell line. Finally, the present application once again proved in the mouse enteritis model induced by sodium dextran sulfate that the screened CNCM I 4644-MAM ​​has a more obvious therapeutic effect than the representative strain A2-165-MAM. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 This is the evolutionary tree of anti-inflammatory microorganisms of the genus Faecalibacterium;

[0039] Figure 2 The anti-inflammatory results of the anti-inflammatory molecules of the microorganisms of the representative strains of each lineage are shown;

[0040] Figure 3 This is the anti-inflammatory result diagram of the anti-inflammatory molecules of the microorganisms of the strains in lineage A;

[0041] Figure 4 This is the anti-inflammatory result diagram of the anti-inflammatory molecules of the CNCM I 4644 strain microorganisms;

[0042] Figure 5 The results show that the MAM protein of CNCM I 4644 strain significantly improves the colitis induced by dextran sulfate sodium salt (DSS) ( Figure 5 -A: Expression of exogenous MAM proteins; Figure 5 -B is the animal experiment process plan; Figure 5 -C is the weight change of mice after modeling; Figure 5 -D is the amount of water consumed by each mouse per day (ml); Figure 5 -E is HE staining of the colon of mice in each group; Figure 5 -F is pathological score). DETAILED DESCRIPTION

[0043] In order to better illustrate the purpose, technical solutions and advantages of the present application, the present application will be further described below in conjunction with the accompanying drawings and specific embodiments.

[0044] In the following examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.

[0045] In the following examples, pcDNA3.1 was used as the eukaryotic expression vector.

[0046] Example 1: Screening method for anti-inflammatory molecules of Faecalibacterium prausnitzii microorganisms

[0047] This embodiment provides a method for screening anti-inflammatory molecules of Faecalibacterium prausnitzii microorganisms, comprising the following steps:

[0048] 1. Download the genome sequences of 71 strains of Faecalibacterium from the NCBI database, find the gene sequences encoding microbial anti-inflammatory molecules through sequence comparison and translate them into amino acid sequences. Perform Maximum Likelihood evolutionary analysis on the amino acid sequences of the above 100 microbial anti-inflammatory molecules using MEGA-X software, and find that they can be divided into at least 7 lineages, namely lineage A to lineage G. The evolutionary tree of microbial anti-inflammatory molecules of Faecalibacterium is as follows: Figure 1 shown.

[0049] 2. Select one representative strain from each of the seven lineages of the genus Faecalibacterium, namely: A, M21 / 2; B, A2-165; C, KLE1255; D, SG-1377; E, APC942 32-1; F, L2 / 6; G, CNCM I 4575.

[0050] The nucleotide sequences of their microbial anti-inflammatory molecules were codon-optimized (as shown in Table 1) and cloned into the eukaryotic expression vector pcDNA3.1, and co-transfected with the luciferase reporter gene vector of NF-κB or the luciferase reporter gene vector of the inflammatory cytokine TNFα promoter into the intestinal epithelial cell line HCT116 to screen for microbial anti-inflammatory molecules that inhibit the expression of NF-κB and TNFα. The experimental results showed that the microbial anti-inflammatory molecules of the M21 / 2 strain in the A lineage had a stronger inhibitory effect on NF-κB and TNFα ( Figure 2 ).

[0051] The specific experimental steps are as follows:

[0052] a) Codon optimization: Since microbial anti-inflammatory molecules are proteins expressed by the genus Faecalibacterium, the frequency of codon usage in the genus Faecalibacterium is very different from that in humans. In order to improve the expression level of microbial anti-inflammatory molecules in the intestinal epithelial cell line HCT116, the codons in the nucleotide sequence of the microbial anti-inflammatory molecule were adjusted to codons with high frequency of use in human cells, taking into account factors such as codon usage preference, ribosome binding, and mRNA structure. The optimized sequence is shown in Table 1.

[0053] b) Gene cloning: The optimized nucleotide sequence of the microbial anti-inflammatory molecule was synthesized by Sangon Biotechnology Co., Ltd., and the synthetic sequence and the pcDNA3.1 vector were double-digested with HindIII and BamHI restriction sites, respectively. Then, the sequence of the microbial anti-inflammatory molecule was ligated into the pcDNA3.1 vector with ligase, transformed into Top10 competent cells for amplification, and identified.

[0054] c) Luciferase reporter gene screening experiment: pcDNA3.1-MAM, pNF-κB-luc (or pTNF-α-promoter-luc), and pRL-TK (as an internal reference) were co-transfected into HCT116 cell lines. After 48 hours, the cells were collected and lysed. The dual luciferase reporter gene detection kit (promega, #E1910) was used for detection. Among them, the NF-κB luciferase reporter gene vector (pNF-κB-luc, #D2206), the inflammatory cytokine TNFα promoter luciferase reporter gene vector (pTNF-α-promoter-luc, #D2480) and the Renilla luciferase reporter gene vector (pRL-TK, #D2760) were all purchased from Bio-Tech Biotechnology Co., Ltd.

[0055] 3. Five strains of lineage A were further screened, namely: SL3 / 3, AM100 B16A, Fp137, CNCM I 4644 and Fp1160. The nucleotide sequence of the microbial anti-inflammatory molecule was codon-optimized and cloned into the eukaryotic expression vector pcDNA3.1, and co-transfected with the luciferase reporter gene vector of NF-κB or the luciferase reporter gene vector of the inflammatory cytokine TNFα promoter into the intestinal epithelial cell line HCT116, thereby screening out the microbial anti-inflammatory molecule with the strongest inhibitory effect on the expression of NF-κB and TNFalpha, namely the Clostridium prausnitzii microbial anti-inflammatory molecule of the CNCM I 4644 strain (i.e., CNCM I 4644-MAM ​​protein) ( Figure 3 ).

[0056] The amino acid sequence of the Clostridium prausnitzii microbial anti-inflammatory molecule of the CNCM I 4644 strain is shown in SEQ ID NO.1.

[0057] SEQ ID NO.1:

[0058] MMMPANFSAVSENEMTYVMGGSVADYLAPAMGAAQWQNFHKNLITIVGNKYVQGFLDN

[0059] TVNAVFSGTWTPGAGLTGFGGQFSNIWKKNYTDNVTDQSTGAQKFGYGALGVVNSILNVAGNLAAIYNLGFGTAKNIVNENKFGF.

[0060] 4. The eukaryotic expression vectors (pcDNA3.1-CNCM I 4644-MAM) of different doses of CNCM I 4644-MAM ​​protein were co-transfected with the NF-κB luciferase reporter gene vector or the luciferase reporter gene vector of the inflammatory cytokine TNFα promoter into the intestinal epithelial cell line HCT116. It was found that the anti-inflammatory molecule of the Faecalibacterium prausnitzii microorganism still had a strong anti-inflammatory effect even when the expression level was very low ( Figure 4 ).

[0061] Table 1

[0062]

[0063]

[0064]

[0065]

[0066] Example 2: Animal Experiment

[0067] To further explore the anti-inflammatory effect of CNCM I 4644-MAM ​​protein in vivo, the results Figure 5 .

[0068] The present application extracted the representative strain A2-165-MAM protein and CNCM I 4644-MAM ​​protein of Clostridium prausnitzii through a conventional Escherichia coli exogenous expression and purification system. The specific steps are as follows: the nucleotide sequences of A2-165-MAM and CNCM I 4644-MAM ​​were cloned into the pET-28a(+) vector with the His tag CATCATCACCATCACCAT inserted into the C-terminus, and the two vectors were amplified using DH5α competent cells, and the two vectors were respectively transferred into BL21 competent cells, and induced to express with 1 mg / ml IPTG in a shaking incubator at 18°C, and then the two MAM proteins were extracted and purified using a His tag protein purification kit (purchased from Beyotime, #P2229S). The expression of MAM protein was detected by Western method. Figure 5 -A.

[0069] Afterwards, 8-week-old C57 male mice were selected and gavaged with 0.5 mg / mouse / day. The control group was gavaged with an equal volume of PBS. After 6 days, the mice were allowed to drink 3% DSS water freely to establish the enteritis model. The control group drank normal sterile water. The model was stopped after 7 days. On the 9th day, the mice were killed and the intestinal tissues were taken for HE staining ( Figure 5 -B). The results showed that the mice in the normal control group grew well and their weight gradually increased; while the mice in the model group had a significant weight loss from the fourth day of the experiment, and their weight decreased by about 20% on the eighth day. Compared with the model group and the A2-165 strain MAM protein gavage group, the weight loss of mice gavaged with CNCM I 4644-MAM ​​protein was relatively slow, less than 10% ( Figure 5 -C). The amount of water each mouse drinks per day (ml) is as follows Figure 5 -D as shown.

[0070] Colon HE staining showed that the colon mucosal epithelium of the normal group of mice was intact, with abundant goblet cells, neatly arranged glandular structures, and no obvious neutrophil infiltration in the lamina propria. The colon pathology of the enteritis model group showed: epithelial integrity was destroyed, goblet cells were missing, glands were deformed, and crypts were twisted and irregular; A2-165-MAM protein intervention could alleviate epithelial destruction to a certain extent. However, the pathological relief effect of the CNCM I4644-MAM ​​protein intervention group was more obvious, as shown by an increase in the number of goblet cells, the recovery of some glands, and a certain degree of reduction in the inflammatory cell infiltration in the mucosal lamina propria. The histopathological score was significantly different from that of the A2-165 group (P<0.05) ( Figure 5 -E and Figure 5 -F).

[0071] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present application rather than to limit the scope of protection of the present application. Although the present application has been described in detail with reference to the preferred embodiments, ordinary technicians in this field should understand that the technical solution of the present application can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present application.

Claims

1. A Faecalibacterium prausnitzii microbial anti-inflammatory molecule, characterized in that The amino acid sequence of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule is as shown in (a) or (b); (a) the amino acid sequence is shown in SEQ ID NO.1; (b) A protein derived from (a) having anti-inflammatory activity, wherein the amino acid sequence in (a) is substituted, deleted or added with one or more amino acids.

2. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the Faecalibacterium prausnitzii microbial anti-inflammatory molecule of claim 1.

3. An expression vector, characterized in that: The expression vector carries the nucleic acid molecule of claim 2.

4. The expression vector according to claim 3, characterized in that The expression vector comprises the eukaryotic expression vector pcDNA3.

1.

5. A host cell, characterized in that The host cell comprises the Faecalibacterium prausnitzii microbial anti-inflammatory molecule of claim 1 or the nucleic acid molecule of claim 2 or the expression vector of claim 3.

6. The host cell according to claim 5, characterized in that The NF-κB luciferase reporter gene vector or the inflammatory cytokine TNFα promoter luciferase reporter gene vector is transferred into the host cell.

7. A method for screening anti-inflammatory molecules of Faecalibacterium prausnitzii as claimed in claim 1, characterized in that: The following steps are involved: S1. Obtain the genome sequences of different strains of Faecalibacterium from the NCBI database; S2. The microbial anti-inflammatory molecules of different strains of Faecalibacterium are cloned into eukaryotic expression vectors, and co-transfected into host cells with NF-κB luciferase reporter gene vector or luciferase reporter gene vector of inflammatory cytokine TNFα promoter, to screen Faecalibacterium prausnitzii microbial anti-inflammatory molecules that have inhibitory effects on the expression of NF-κB and TNFα.

8. A method for grouping Faecalibacterium prausnitzii, characterized in that: The amino acid series of the anti-inflammatory molecule of the Faecalibacterium prausnitzii microorganism as claimed in claim 1 was subjected to phylogenetic tree analysis.

9. An anti-inflammatory drug, characterized in that: The anti-inflammatory drug comprises the Faecalibacterium prausnitzii microbial anti-inflammatory molecule as claimed in claim 1.

10. Use of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule according to claim 1 in the preparation of anti-inflammatory drugs.

Citation Information

Patent Citations

  • Agent for the prevention or treatment of fat-related diseases and / or inflammation

    CN111107860A

  • Reg3alpha for use in the protection of oxygen sensitive gram-positive bacteria

    CN112004549A

  • Application of Faecalibacterium prausnitzii in relieving allergic asthma and rhinitis Th2 reaction

    CN112402459A

  • Application of clostridium praeparatum in preparation of product for preventing, improving and / or treating acute pancreatitis

    CN116650533A

  • Anti-inflammatory peptides

    US20150335705A1

Cited By

  • Clostridium pralaense capable of improving metabolism-related steatohepatitis and application of clostridium pralaense

    CN119265085A

  • Recombinant clostridium praeparatum fpPRPS protein as well as preparation method and application thereof

    CN121627846A

  • Lactococcus lactis and application thereof in preparation of medicine for improving tumor treatment related diarrhea

    CN122381986A